Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Misonix Subsidiary Sonora Medical Awarded U.S. Patent for Ultrasound Testing Device

Wednesday, October 17, 2007

Enhanced Intellectual Property Position for Development of Ultrasonic Medical Devices

Farmingdale, NY -- Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that its Sonora Medical Systems, Inc. subsidiary was awarded U.S. Patent No. 7,278,289 by the Director of the United States Patent and Trademark Office. The patent awarded to Sonora, a leading supplier of aftermarket products, services and test equipment to the medical imaging ultrasound and MRI markets, is the first for its unique FirstAssist ultrasound system testing device and pertains to the methods and apparatus for testing a diagnostic ultrasound system having multiple transmitter elements and multiple receiver elements. FirstAssist was designed and developed for the purposes of testing the accuracy and ensuring the clinical efficacy of medical ultrasound imaging devices.

Leading the development of FirstAssist and the authors of the patent are James Gessert, G. Wayne Moore and William Phillips. Commenting on the patent award, G. Wayne Moore, President and CEO of Sonora, said: "This patent marks the 7th U.S. patent awarded to Sonora and the first patent specific to our exciting new FirstAssist device. As a leader in the development of products and services for both the ultrasound and MRI markets, we believe our FirstAssist device, as well as our other proprietary technologies, such as FirstCall and the Nickel, position us to better serve the industry."

"We are pleased to announce the latest achievements for Misonix with the launch of Sonora Medical Systems’ FirstAssist device and the receipt of its first patent. Sonora and the entire medical device team at Misonix continue to innovate with novel technologies underlying our extensive platform of therapeutic and diagnostic products," commented Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We have collectively been issued a total of 45 patents with an additional 19 patents pending (published and non-published). This impressive intellectual property portfolio enables the development of ultrasonic medical devices by Misonix that substantially improve the quality of healthcare delivered to patients worldwide."

FirstAssist tests the various performance characteristics of the ultrasound system’s B-mode, Doppler, and Color Flow modalities. The device directly interrogates diagnostic ultrasound systems by injecting signals of various amplitudes, phases and frequencies through a computer controlled probe simulator interface connected to the ultrasound system’s probe port. FirstAssist is used by Biomedical Engineers and Medical Imaging Physicists to establish a baseline of performance for any given system from a multitude of manufacturers as part of acceptance testing, as an integral part of an ongoing hospital-based ultrasound EBQA program, and for system troubleshooting.

FirstAssist has multiple patents pending. The FirstAssist system and other Sonora ultrasound test devices will be featured at the 2007 Radiological Society of North America (RSNA) meeting from November 25-30 in Chicago at McCormick Place, South Building, Hall A, Booth Number 3392.

About Sonora Medical Systems, Inc.

Sonora Medical Systems, a subsidiary of Misonix, Inc. (Nasdaq: MSON), is an ISO-9000/13485 certified provider of high quality products and services to the diagnostic ultrasound and MRI markets. Its products and services are marketed on a direct basis to healthcare providers, dealers and service organizations in North America, and others directly and through distribution partners in non-U.S. markets. Customers include large and small hospitals, stand-alone imaging centers, clinics, Independent Service Organizations (ISOs) and Original Equipment Manufacturers (OEMs). Additional information on Sonora is available at its web site at

About Misonix

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures, and markets, therapeutic ultrasonic medical devices, and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissue without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free